The table below shows Dianthus Therapeutics, Inc. /DE/'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$28.86M
-$27.63M
-$14.94M
-$10.28M
-$19.74M
-$16.77M
Capital expenditure
-
-
-
$245.00K
$27.00K
$7.00K
Investing cash flow
-$133.97M
$14.79M
-$5.51M
$18.13M
-$40.14M
$7.49M
Dividends paid
-
-
-
-
DNTH operating cash flow (10-K history)
Dianthus Therapeutics, Inc. /DE/ reported operating cash flow of -$129.06M for fiscal year 2025. That is down 65.1% from -$78.18M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$6.53M (FY 2016) to -$129.06M. Figures come from the company's audited annual reports as filed with the SEC.